S-1: 180 Life Sciences Files for Resale of Up to 13.95 Million Shares Issuable Upon Warrant Exercise

180 Life Sciences Corp. is registering for resale up to 13.95 million shares of its common stock potentially issuable upon the exercise of existing warrants held by a selling stockholder.

Summary

• 180 Life Sciences Corp. has filed a registration statement for the resale of up to 13,950,976 shares of its common stock.
• These shares are issuable upon the exercise of warrants held by a single selling stockholder.
• The warrants consist of (i) 9,064,098 shares of common stock issuable upon the exercise of the December 2023 Pre-Funded Warrants, and (ii) 4,886,878 shares of common stock issuable upon the exercise of the December 2023 Common Warrants.
• The company will not receive any proceeds from the sale of these shares by the selling stockholder, except for approximately $1,540,897 if all December 2023 Common Warrants are exercised for cash.
• These proceeds, if received, are intended for research and development, general corporate purposes, and potential expenses related to a reverse merger and legal expenses.
• The selling stockholder will determine the timing and amounts of any sales, which may occur through public or private transactions at prevailing market prices or negotiated prices.
• As of January 30, 2024, the last reported sale price of the company's common stock was $0.2046 per share.
• The company's future is subject to various risks, including the need for additional funding, dependence on product candidate success, competition, and regulatory approvals.

Sentiment

Score: 4

Explanation: The document is primarily factual and descriptive, outlining the details of a securities registration. While it mentions potential benefits from warrant exercises, it also acknowledges significant risks and uncertainties, resulting in a neutral to slightly negative sentiment.

Positives

• If all December 2023 Common Warrants are exercised for cash, the company could receive up to approximately $1,540,897.
• The company intends to use any proceeds from the exercise of the December 2023 Common Warrants for research and development, and general corporate purposes, including the potential expenses related to completing a reverse merger and legal expenses.

Negatives

• The company will not receive any proceeds from the sale of the Shares by the Selling Stockholder.
• The company's future is subject to various risks, including the need for additional funding, dependence on product candidate success, competition, and regulatory approvals.

Risks

• The company is a clinical stage biotechnology company with no revenue for the years ended December 31, 2022 and 2021 or the nine months ended September 30, 2023, and does not anticipate generating revenue for the near future.
• The company needs additional financing, both near term and long term, to support its operations, and there is no assurance that it will be able to raise such financing as needed.
• The company is dependent on the success of its future product candidates, some of which may not receive regulatory approval or be successfully commercialized.
• The company faces intense competition from companies with greater resources and experience than it has.
• The company's ability to receive regulatory approvals for its product candidates is uncertain, and the timeline and costs associated therewith are unknown.
• The company's future product candidates, if approved by regulatory authorities, may be unable to achieve the expected market acceptance.
• The company may be subject to litigation and damages for its failure to pay amounts due to Oxford, and may be forced to pay interest and penalties, which funds it does not currently have.
• The company is not in compliance with the continued listing standards of Nasdaq, may not be able to comply with Nasdaqs continued listing standards in the future, and as a result its common stock and warrants may be delisted from Nasdaq.
• The company does not currently have any independent directors or an audit committee, it does not currently have $2.5 million or more of stockholders equity, and its common stock trading price is below $1.00 per share, and as a result, it is not in compliance with the continued listing requirements of the Nasdaq Capital Market and its Common Stock and Public Warrants are subject to delisting.

Future Outlook

The company intends to use any proceeds from the exercise of the December 2023 Common Warrants for research and development, and general corporate purposes, including the potential expenses related to completing a reverse merger and legal expenses.

Industry Context

The document highlights the competitive and highly regulated nature of the pharmaceutical industry, emphasizing the need for successful product development, regulatory approvals, and market acceptance to generate revenue and achieve profitability.

Comparison to Industry Standards

• The document mentions competitors like Insys Therapeutics, Zogenix, and Biocodex, which are developing treatments for similar indications, highlighting the competitive landscape.
• The document does not provide specific comparisons to industry standards or benchmarks in terms of financial performance, clinical trial outcomes, or market share.
• The document does not provide specific comparisons to comparable companies, projects, or results.

Stakeholder Impact

• The potential sale of shares by the selling stockholder could impact the share price and liquidity of the company's stock, affecting current shareholders.
• The company's ability to fund research and development and pursue strategic alternatives depends on its financial resources, which could impact its ability to develop new treatments and create value for stakeholders.

Next Steps

• The selling stockholder may offer such Shares from time to time as it may determine through public or private transactions or through other means described in the section entitled Plan of Distribution beginning on page 161 of this prospectus, at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices.

Key Dates

Keywords

resale, common stock, warrants, 180 Life Sciences, registration statement, selling stockholder, securities, exercise, ATNF, biotechnology